Article

Long-term etanercept use for severe generalized psoriasis in an HIV-infected individual: a case study.

University of California, San Francisco, Department of Dermatology, USA.
Journal of drugs in dermatology: JDD (Impact Factor: 1.32). 03/2012; 11(3):413-4.
Source: PubMed

ABSTRACT The treatment options for psoriasis in HIV-infected individuals are limited due to the immunosuppressive nature of the therapeutic modalities and the patient's immunocompromised state. Etanercept has been shown to be safe and effective in the non-HIV psoriasis population with nearly 20 years of experience. However, there is limited data on the safety of etanercept use in the HIV patient population. The authors report a case of an HIV-infected patient with psoriasis who has remained mostly clear on continuous, uninterrupted etanercept use for over six years.

0 Followers
 · 
100 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Etanercept is a systemic tumor necrosis factor-α inhibitor indicated for use in the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis. A considerable number of studies have demonstrated the efficacy and safety of etanercept in these indications, thus offering a new and promising treatment option. The drug was approved by the Food and Drug Administration in the United States and by the European Medicines Evaluation Agency in Europe for treating moderate-to-severe psoriasis in 2004. This article reviews the pharmacology, clinical efficacy and safety of etanercept for psoriasis and recent findings since its approval. The number of studies of medium- and long-term efficacy and safety is increasing steadily; these studies support the use of etanercept in a maintenance setting, with an apparently more favorable risk: benefit ratio than traditional systemic treatments.
    Expert Review of Dermatology 01/2014; 8(4). DOI:10.1586/17469872.2013.814880
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To date, anti-tumor necrosis factor alfa (anti-TNF-α) therapy is the only alternative to nonsteroidal anti-inflammatory drugs for the treatment of ankylosing spondylitis. Etanercept is a soluble TNF receptor, with a mode of action and pharmacokinetics different to those of antibodies and distinctive efficacy and safety. Etanercept has demonstrated efficacy in the treatment of ankylosing spondylitis, with or without radiographic sacroiliitis, and other manifestations of the disease, including peripheral arthritis, enthesitis, and psoriasis. Etanercept is not efficacious in inflammatory bowel disease, and its efficacy in the treatment of uveitis appears to be lower than that of other anti-TNF drugs. Studies of etanercept confirmed regression of bone edema on magnetic resonance imaging of the spine and sacroiliac joint, but failed to reduce radiographic progression, as do the other anti-TNF drugs. It seems that a proportion of patients remain in disease remission when the etanercept dose is reduced or administration intervals are extended. Etanercept is generally well tolerated with an acceptable safety profile in the treatment of ankylosing spondylitis. The most common adverse effect of etanercept treatment is injection site reactions, which are generally self-limiting. Reactivation of tuberculosis, reactivation of hepatitis B virus infection, congestive heart failure, demyelinating neurologic disorders, hematologic disorders like aplastic anemia and pancytopenia, vasculitis, immunogenicity, and exacerbation or induction of psoriasis are class effects of all the anti-TNF drugs, and have been seen in patients with ankylosing spondylitis. However, etanercept is less likely to induce reactivation of tuberculosis than the other anti-TNF drugs and it has been suggested that etanercept might be less immunogenic, especially in ankylosing spondylitis. Acute uveitis, Crohn's disease, and sarcoidosis are other adverse events that have been rarely associated with etanercept therapy in patients with ankylosing spondylitis.
    Patient Preference and Adherence 01/2013; 7:961-972. DOI:10.2147/PPA.S33109 · 1.49 Impact Factor